Amgen stock heads into the open after a 1.1 percent gain
Published on 09/15/2026 at 07:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen stock closed at USD 381.96 on Nasdaq on September 14, 2026, up roughly 1.1 percent from the prior session, with intraday trading between USD 376.37 and USD 384.53 per Nasdaq data reflected by Robinhood.
September 14, 2026 in numbers
Amgen Inc. (ISIN US0311621009, Nasdaq: AMGN) ended the session on September 14, 2026 at USD 381.96 on Nasdaq, gaining about 1.1 percent compared with its previous close, while the day range stretched from USD 376.37 to USD 384.53 according to Robinhood quote data.Robinhood The move came in a broader market session where the S&P 500 declined 0.5 percent to 7,619.98 and the Nasdaq Composite fell 0.6 percent, underscoring that Amgen outperformed major indices on September 14, 2026.Investopedia Sector context was mixed, as healthcare stocks were cited as having their biggest weekly drop in months, with Amgen among the names under pressure.TradeStation
A specific driver around Amgen was competitive news in the cardiovascular drug space, as Novartis reported negative trial developments for its pelacarsen candidate, and Amgen's share price was described as having recently fallen about 10 percent in that context, highlighting investor sensitivity to developments in lipid-lowering therapies.The Motley Fool At the same time, valuation commentary from GuruFocus characterized Amgen as modestly overvalued versus an intrinsic value estimate, reinforcing that the stock traded at a premium to some fundamental models around mid-September 2026.GuruFocus
Today’s catalysts for Amgen
Today, September 15, 2026, attention around Amgen focuses on recent regulatory and sector developments rather than a specific scheduled corporate event. On September 14, 2026, the US Food and Drug Administration approved a reduced monitoring time for the first two doses of Amgen's bispecific T-cell engager therapy Imdelltra, which simplifies the treatment protocol and could influence adoption trends in oncology, as detailed in an Amgen company press release.Amgen This regulatory update, combined with ongoing commentary about Amgen's dividend profile and valuation from research outlets such as GuruFocus, may continue to shape sentiment as trading resumes today without a clearly flagged earnings or annual meeting date within the next few days.GuruFocus
